252 related articles for article (PubMed ID: 33686772)
1. Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study.
Takahashi S; Fujiwara Y; Nakano K; Shimizu T; Tomomatsu J; Koyama T; Ogura M; Tachibana M; Kakurai Y; Yamashita T; Sakajiri S; Yamamoto N
Cancer Sci; 2021 Jun; 112(6):2361-2370. PubMed ID: 33686772
[TBL] [Abstract][Full Text] [Related]
2. A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas.
Gounder MM; Bauer TM; Schwartz GK; Weise AM; LoRusso P; Kumar P; Tao B; Hong Y; Patel P; Lu Y; Lesegretain A; Tirunagaru VG; Xu F; Doebele RC; Hong DS
J Clin Oncol; 2023 Mar; 41(9):1714-1724. PubMed ID: 36669146
[TBL] [Abstract][Full Text] [Related]
3. Phase I study of daily and weekly regimens of the orally administered MDM2 antagonist idasanutlin in patients with advanced tumors.
Italiano A; Miller WH; Blay JY; Gietema JA; Bang YJ; Mileshkin LR; Hirte HW; Higgins B; Blotner S; Nichols GL; Chen LC; Petry C; Yang QJ; Schmitt C; Jamois C; Siu LL
Invest New Drugs; 2021 Dec; 39(6):1587-1597. PubMed ID: 34180037
[TBL] [Abstract][Full Text] [Related]
4. Phase I dose-escalation study of milademetan in patients with relapsed or refractory acute myeloid leukemia.
Sekiguchi N; Kasahara S; Miyamoto T; Kiguchi T; Ohno H; Takagi T; Tachibana M; Sumi H; Kakurai Y; Yamashita T; Usuki K
Int J Hematol; 2023 Jan; 117(1):68-77. PubMed ID: 36258088
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of SAR405838, a novel human double minute 2 (HDM2) antagonist, in patients with solid tumours.
de Jonge M; de Weger VA; Dickson MA; Langenberg M; Le Cesne A; Wagner AJ; Hsu K; Zheng W; Macé S; Tuffal G; Thomas K; Schellens JH
Eur J Cancer; 2017 May; 76():144-151. PubMed ID: 28324749
[TBL] [Abstract][Full Text] [Related]
6. Model-based assessments of CYP3A-mediated drug-drug interaction risk of milademetan.
Hong Y; Ishizuka T; Watanabe A; Tachibana M; Lee M; Ishizuka H; LaCreta F; Abutarif M
Clin Transl Sci; 2021 Nov; 14(6):2220-2230. PubMed ID: 34080309
[TBL] [Abstract][Full Text] [Related]
7. Phase I dose-escalating study of panobinostat (LBH589) administered intravenously to Japanese patients with advanced solid tumors.
Morita S; Oizumi S; Minami H; Kitagawa K; Komatsu Y; Fujiwara Y; Inada M; Yuki S; Kiyota N; Mitsuma A; Sawaki M; Tanii H; Kimura J; Ando Y
Invest New Drugs; 2012 Oct; 30(5):1950-7. PubMed ID: 21964801
[TBL] [Abstract][Full Text] [Related]
8. Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia.
Uy GL; Assouline S; Young AM; Blotner S; Higgins B; Chen LC; Yee K
Invest New Drugs; 2020 Oct; 38(5):1430-1441. PubMed ID: 32020437
[TBL] [Abstract][Full Text] [Related]
9. A phase 1 study of the MDM2 antagonist RO6839921, a pegylated prodrug of idasanutlin, in patients with advanced solid tumors.
Abdul Razak AR; Miller WH; Uy GL; Blotner S; Young AM; Higgins B; Chen LC; Gore L
Invest New Drugs; 2020 Aug; 38(4):1156-1165. PubMed ID: 31734832
[TBL] [Abstract][Full Text] [Related]
10. Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.
Koyama T; Shimizu T; Kojima Y; Sudo K; Okuma HS; Shimoi T; Ichikawa H; Kohsaka S; Sadachi R; Hirakawa A; Yoshida A; Ando RM; Ueno T; Yanagaki M; Matsui N; Nakamura K; Yamamoto N; Yonemori K
Cancer Discov; 2023 Aug; 13(8):1814-1825. PubMed ID: 37369013
[TBL] [Abstract][Full Text] [Related]
11. A single-center, open-label study investigating the excretion balance, pharmacokinetics, metabolism, and absolute bioavailability of a single oral dose of [
Pápai Z; Chen LC; Da Costa D; Blotner S; Vazvaei F; Gleave M; Jones R; Zhi J
Cancer Chemother Pharmacol; 2019 Jul; 84(1):93-103. PubMed ID: 31062077
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and preliminary efficacy of the PARP inhibitor talazoparib in Japanese patients with advanced solid tumors: phase 1 study.
Naito Y; Kuboki Y; Ikeda M; Harano K; Matsubara N; Toyoizumi S; Mori Y; Hori N; Nagasawa T; Kogawa T
Invest New Drugs; 2021 Dec; 39(6):1568-1576. PubMed ID: 34160752
[TBL] [Abstract][Full Text] [Related]
13. Phase I study of TAS-115, a novel oral multi-kinase inhibitor, in patients with advanced solid tumors.
Doi T; Matsubara N; Kawai A; Naka N; Takahashi S; Uemura H; Yamamoto N
Invest New Drugs; 2020 Aug; 38(4):1175-1185. PubMed ID: 31820255
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of the MET inhibitor tepotinib in Japanese patients with solid tumors.
Shitara K; Yamazaki K; Tsushima T; Naito T; Matsubara N; Watanabe M; Sarholz B; Johne A; Doi T
Jpn J Clin Oncol; 2020 Aug; 50(8):859-866. PubMed ID: 32328660
[TBL] [Abstract][Full Text] [Related]
15. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.
Kuppens IE; Witteveen PO; Schot M; Schuessler VM; Daehling A; Beijnen JH; Voest EE; Schellens JH
Invest New Drugs; 2007 Jun; 25(3):227-35. PubMed ID: 17146730
[TBL] [Abstract][Full Text] [Related]
16. Phase I and pharmacokinetic study of the novel oral cell-cycle inhibitor Ro 31-7453 in patients with advanced solid tumors.
Dupont J; Bienvenu B; Aghajanian C; Pezzulli S; Sabbatini P; Vongphrachanh P; Chang C; Perkell C; Ng K; Passe S; Breimer L; Zhi J; DeMario M; Spriggs D; Soignet SL
J Clin Oncol; 2004 Aug; 22(16):3366-74. PubMed ID: 15310782
[TBL] [Abstract][Full Text] [Related]
17. Phase I dose-escalation trial of the oral investigational Hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors.
Goldman J; Eckhardt SG; Borad MJ; Curtis KK; Hidalgo M; Calvo E; Ryan DP; Wirth LJ; Parikh A; Partyka J; Faessel H; Gangolli E; Stewart S; Rosen LS; Bowles DW
Clin Cancer Res; 2015 Mar; 21(5):1002-9. PubMed ID: 25501576
[TBL] [Abstract][Full Text] [Related]
18. Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
Gluck WL; Gounder MM; Frank R; Eskens F; Blay JY; Cassier PA; Soria JC; Chawla S; de Weger V; Wagner AJ; Siegel D; De Vos F; Rasmussen E; Henary HA
Invest New Drugs; 2020 Jun; 38(3):831-843. PubMed ID: 31359240
[TBL] [Abstract][Full Text] [Related]
19. Safety, pharmacokinetics, and efficacy of AMG 706, an oral multikinase inhibitor, in patients with advanced solid tumors.
Rosen LS; Kurzrock R; Mulay M; Van Vugt A; Purdom M; Ng C; Silverman J; Koutsoukos A; Sun YN; Bass MB; Xu RY; Polverino A; Wiezorek JS; Chang DD; Benjamin R; Herbst RS
J Clin Oncol; 2007 Jun; 25(17):2369-76. PubMed ID: 17557949
[TBL] [Abstract][Full Text] [Related]
20. A Phase I dose-escalation, pharmacokinetics and food-effect study of oral donafenib in patients with advanced solid tumours.
Li X; Qiu M; Wang S; Zhu H; Feng B; Zheng L
Cancer Chemother Pharmacol; 2020 Mar; 85(3):593-604. PubMed ID: 32008115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
